Select Vaccines' key technology is a specialised vaccine platform and discovery company focused principally on developing its unique and high impact vaccine technology for viral and parasitic diseases. Select has patents pending for a novel approach to virus-like particle (VLP) development that makes vaccine design faster and potentially more effective than older vaccine technology. The company also holds patents on a novel target for small molecule antivirals that is present in picornaviruses (the cause of a wide range of human diseases), as well as a range of diagnostic products.

The vaccine product portfolio is all early-stage research, and the company plans to continue finding licensing partners to fund its technology development. The proprietary VLP technology has applications in several important therapeutic areas.